Plain-English translation of NCT06979492 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether regular blood transfusions during pregnancy can help prevent serious complications in women with sickle cell disease. Sickle cell disease causes red blood cells to become stiff and block blood vessels, which can lead to severe pain, organ damage, and dangerous complications during pregnancy. Researchers want to know if blood transfusions can protect both mother and baby during this critical time.
Pregnant women with sickle cell disease face much higher rates of life-threatening complications—including severe pain crises, chest emergencies, and miscarriage—compared to pregnant women without the disease. While blood transfusions are already used to prevent stroke and prepare patients for surgery, no one has studied whether regular transfusions during pregnancy actually prevent pregnancy-related complications, and doctors currently decide on a case-by-case basis whether to offer this treatment.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to either receive regular blood transfusions throughout your pregnancy or receive standard care without transfusions. If assigned to receive transfusions, you will have your first transfusion between 6 and 20 weeks of pregnancy, followed by repeat transfusions every 3 to 6 weeks. The study team will monitor your blood counts to keep a specific level of sickle hemoglobin low, and you will continue in the study through delivery and shortly after.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States